World Oncology Cell Therapy Congress (WOCTC)

The chief medical officer of Trisalus Life Sciences discussed studies evaluating the company’s PEDD system.

The vice president of business development and alliances at Prescient Therapeutics discussed advantages of the OmniCAR, SpyTag, and SpyCatcher technologies.

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed progress of the phase 1 trial and possible future evaluations of the therapy.

The cell therapy field applications staff scientist at ThermoFisher discussed advantages of the company’s DynaCellect system.

The head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

The chief medical officer of Trisalus Life Sciences discussed the company’s PEDD system and SD-101.

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

The vice president of business development and alliances at Prescient Therapeutics discussed the mechanism of the OmniCAR technology.

The associate director of research at Lyell Immunopharma discussed the company’s programs and newest technologies aimed at solid tumors.